Vice President, Head of Translational Medicine, Oncology Development, Clinical Operations and P&PM, LianBio IFPMA ICH M13 Alternate
Industry Supervisor, National Key Laboratory of Biotherapy, West China Hospital
Executive Committee Member, US China Anti Cancer Association
Member of the Standing Committee, Professional Committee of Oncology Clinical Research, China Medicine Education Association
Member, Professional Committee of Pharmacometrics, Chinese Pharmacology Society
Member, Professional Committee of Clinical Research, Chinese Anti Cancer Association
Member, Professional Committee of Clinical Research, Shanghai Pharmacy Association
Dr. Levvy Lv holds a doctorate degree in Clinical Pharmacology and is the Vice President, Head of Translational Medicine, Oncology Development, Clinical Operations and P&PM of LianBio. He built and is in charge of Clinical Pharmacology, Oncology and Infectious Diseases Medical, Biomarker and Companion Diagnosis, Clinical Operations, Data Science, Clinical Trial Supply, Training & QC, P&PM and CMC; he also built and dotted line managed Clinical QA and Clinical Procurement. He has more than 10 years’ experience in clinical research in China, US, Europe and Asia Pacific. He has led multiple programs and has rich experience in integrating with regulatory agencies.
Dr. Lv has significant publications at top journals such as The Lancet Oncology, Antimicrobial Agents and Chemotherapy，et al and has given oral presentations at top congress such as ASM, APC, et al. He is also the editorial member of the textbook Pharmacokinetics-Pharmacodynamics: Theories and Applications
Before joining LianBio, Dr. Lv worked for CSPC, Covance, Roche and GSK.
临床药理学、定量药理学博士
现任联拓生物转化医学、肿瘤开发、临床运营和项目组合及项目管理副总裁
IFPMA ICH M13专家组候任组长
华西医院生物治疗国家重点实验室研究生产业导师
美中抗癌协会执行委员会委员
中国医药教育协会肿瘤临床研究专委会常委
中国药理学会定量药理专委会委员
中国抗癌协会临床研究专委会委员
上海市药学会药物临床研究专委会委员
现任联拓生物转化医学、肿瘤开发、临床运营和项目组合及项目管理副总裁
IFPMA ICH M13专家组候任组长
华西医院生物治疗国家重点实验室研究生产业导师
美中抗癌协会执行委员会委员
中国医药教育协会肿瘤临床研究专委会常委
中国药理学会定量药理专委会委员
中国抗癌协会临床研究专委会委员
上海市药学会药物临床研究专委会委员
现任联拓生物转化医学、肿瘤开发、临床运营和项目组合及项目管理副总裁，建立并负责公司临床药理和定量药理、生物标志物和伴随诊断、肿瘤和抗感染医学、临床运营、统计和数据管理、培训和质控、CMC、临床研究供应链、管线及项目管理部门，建立并虚线管理临床QA和临床采购部门。具有十余年的药物开发经验，从业经历涵盖了I期到IV期的临床开发全过程，涉及治疗领域包括肿瘤、抗感染、神经、精神、心血管、内分泌、泌尿、皮肤、肾病、罕见病等，曾主持过多项在中国大陆、美国、荷兰、新西兰、澳大利亚、新加坡、马来西亚、韩国、日本、中国香港、中国台湾等国家和地区开展的临床研究，多次主导和参与与主要国家药监部门的技术交流沟通。
曾以第一作者身份在The Lancet Oncology, Antimicrobial Agents and Chemotherapy等杂志上发表论文数篇，并在美国微生物学年会、亚洲定量药理学年会等国际学术会议上做过口头报告。担任科学出版社《药动学-药效学：理论与应用》教材编委。
加入联拓生物前曾在石药集团、科文斯、罗氏和葛兰素史克公司从事过多年临床开发相关工作。